Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19
Status:
Completed
Trial end date:
2020-12-21
Target enrollment:
Participant gender:
Summary
A Phase 2 study to evaluate the safety and preliminary efficacy of ATYR1923, compared to
placebo, in hospitalized patients with SARS-CoV-2 (COVID-19) severe pneumonia not requiring
mechanical ventilation